Endocrine

, Volume 43, Issue 3, pp 626–634

Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status

  • Heidi Marie Christensen
  • Caroline Kistorp
  • Morten Schou
  • Niels Keller
  • Bo Zerahn
  • Jan Frystyk
  • Peter Schwarz
  • Jens Faber
Original Article

DOI: 10.1007/s12020-012-9836-3

Cite this article as:
Christensen, H.M., Kistorp, C., Schou, M. et al. Endocrine (2013) 43: 626. doi:10.1007/s12020-012-9836-3

Abstract

The prevalence of cardiac cachexia has previously been estimated to 8–42 %. However, novel treatment strategies for chronic heart failure (CHF) have improved and decreased morbidity and mortality. Therefore, we aimed to reassess the prevalence of cachexia in an outpatient CHF clinic and to characterize a CHF population with and without cachexia with respect to body composition and related biomarkers. From 2008 to 2011, we screened 238 optimally treated, non-diabetic CHF patients for cardiac cachexia, defined as unintentional non-oedematous weight loss of >5 % over ≥6 months. CHF patients (LVEF <45 %) with cachexia (n = 19) and without (n = 19) were compared to controls with prior myocardial infarction and left ventricular ejection fraction (LVEF) >45 % (n = 19). The groups were matched for age, sex, and kidney function. Body composition was assessed by dual energy X-ray absorptiometry. The prevalence of cachexia was 10.5 %. Abdominal fat ± SD (%) was reduced in cachectic CHF: 27.4 ± 10.0 versus 37.5 ± 10.6 % (CHF, no cachexia) and 40.6 ± 8.0 % (controls), (P < 0.001). NT-proBNP levels were inversely correlated to abdominal fat in a multivariate linear regression analysis adjusted for known predictors of NT-proBNP (LVEF and NYHA); (β = −0.28; P = 0.018). Myostatin levels were reduced in cachectic CHF compared to controls (P = 0.013). The prevalence of cachexia in stable CHF, treated according to recent guidelines, is lower than previously anticipated. Body alterations in cachexia consist mainly of reduced abdominal fat mass, and its inverse correlation to NT-proBNP suggests involvement of abdominal lipolysis. Our data do not support a role of circulating myostatin as a biomarker for muscle wasting.

Keywords

Chronic heart failureCardiac cachexiaBody compositionPrevalenceBiomarkers

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Heidi Marie Christensen
    • 1
    • 2
    • 3
  • Caroline Kistorp
    • 1
  • Morten Schou
    • 4
  • Niels Keller
    • 2
  • Bo Zerahn
    • 5
  • Jan Frystyk
    • 6
    • 7
  • Peter Schwarz
    • 8
    • 9
  • Jens Faber
    • 1
    • 9
  1. 1.Department of EndocrinologyHerlev University HospitalHerlevDenmark
  2. 2.Department of CardiologyHerlev University HospitalHerlevDenmark
  3. 3.FrederiksbergDenmark
  4. 4.Department of CardiologyRigshospitalet, University Hospital of CopenhagenCopenhagenDenmark
  5. 5.Department of Clinical Physiology and Nuclear MedicineHerlev University HospitalHerlevDenmark
  6. 6.Medical Research Laboratories, Clinical Institute of MedicineAarhus UniversityAarhusDenmark
  7. 7.Department of Endocrinology and Internal MedicineAarhus University HospitalAarhusDenmark
  8. 8.Department of MedicineGlostrup University HospitalGlostrupDenmark
  9. 9.Faculty of Health SciencesCopenhagen UniversityCopenhagenDenmark